Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)

Claudia Paba-Prada; Antonio Palumbo; Ulf-Henrik Mellqvist; P Voorhees; Torben Plesner; Pieter Sonneveld; C Byrne; J Harmenberg; Eva Nordstrom; Paul Richardson

Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)

Claudia Paba-Prada
, Antonio Palumbo
, Ulf-Henrik Mellqvist
, P Voorhees
, Torben Plesner
, Pieter Sonneveld
, C Byrne
, J Harmenberg
, Eva Nordstrom
, Paul Richardson

Dana–Farber Cancer Institute

Research output: Contribution to conference without publisher/journal › Conference abstract for conference › Research › peer-review

Original language	English
Publication date	2014
Publication status	Published - 2014
Event	56th American Society of Hematology Annual Meeting & Exposition - San Fransisco, CA, United States Duration: 6. Dec 2014 → 9. Dec 2014 Conference number: 56

Conference

Conference	56th American Society of Hematology Annual Meeting & Exposition
Number	56
Country/Territory	United States
City	San Fransisco, CA
Period	06/12/2014 → 09/12/2014

Documents & Links

https://ash.confex.com/ash/2014/webprogram/Paper72880.html

SDU Link

Check access to the material in SDU Library's search engine

Cite this

Paba-Prada, C., Palumbo, A., Mellqvist, U.-H., Voorhees, P., Plesner, T., Sonneveld, P., Byrne, C., Harmenberg, J., Nordstrom, E., & Richardson, P. (2014). Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM). Abstract from 56th American Society of Hematology Annual Meeting & Exposition, San Fransisco, CA, United States. https://ash.confex.com/ash/2014/webprogram/Paper72880.html

Paba-Prada, Claudia ; Palumbo, Antonio ; Mellqvist, Ulf-Henrik et al. / Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM). Abstract from 56th American Society of Hematology Annual Meeting & Exposition, San Fransisco, CA, United States.

@conference{d8daaf50920c4eecb175d9381f2787c1,

title = "Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)",

author = "Claudia Paba-Prada and Antonio Palumbo and Ulf-Henrik Mellqvist and P Voorhees and Torben Plesner and Pieter Sonneveld and C Byrne and J Harmenberg and Eva Nordstrom and Paul Richardson",

year = "2014",

language = "English",

note = "56th American Society of Hematology Annual Meeting \& Exposition ; Conference date: 06-12-2014 Through 09-12-2014",

}

Paba-Prada, C, Palumbo, A, Mellqvist, U-H, Voorhees, P, Plesner, T, Sonneveld, P, Byrne, C, Harmenberg, J, Nordstrom, E & Richardson, P 2014, 'Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)', 56th American Society of Hematology Annual Meeting & Exposition, San Fransisco, CA, United States, 06/12/2014 - 09/12/2014. <https://ash.confex.com/ash/2014/webprogram/Paper72880.html>

Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM). / Paba-Prada, Claudia; Palumbo, Antonio; Mellqvist, Ulf-Henrik et al.
2014. Abstract from 56th American Society of Hematology Annual Meeting & Exposition, San Fransisco, CA, United States.

Research output: Contribution to conference without publisher/journal › Conference abstract for conference › Research › peer-review

TY - ABST

T1 - Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)

AU - Paba-Prada, Claudia

AU - Palumbo, Antonio

AU - Mellqvist, Ulf-Henrik

AU - Voorhees, P

AU - Plesner, Torben

AU - Sonneveld, Pieter

AU - Byrne, C

AU - Harmenberg, J

AU - Nordstrom, Eva

AU - Richardson, Paul

N1 - Conference code: 56

PY - 2014

Y1 - 2014

M3 - Conference abstract for conference

T2 - 56th American Society of Hematology Annual Meeting & Exposition

Y2 - 6 December 2014 through 9 December 2014

ER -

Paba-Prada C, Palumbo A, Mellqvist UH, Voorhees P, Plesner T, Sonneveld P et al.. Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM). 2014. Abstract from 56th American Society of Hematology Annual Meeting & Exposition, San Fransisco, CA, United States.